Effect of oral administration of a continuous 18 day regimen of meloxicam on ovulation: experience of a randomized controlled trial

  • C. Jesam
    Corresponding author at: José Victorino Lastarria 29, apt. 101, Santiago, Santiago, Chile.
    Instituto Chileno de Medicina Reproductiva (ICMER), José Victorino Lastarria 29, apt. 101, Santiago, Santiago, Chile, 8320165

    Instituto de Investigaciones Materno Infantil (IDIMI), Faculty of Medicine Universidad de Chile, Santa Rosa 1234, Santiago, Santiago, Chile, 8360160
    Search for articles by this author
  • A.M. Salvatierra
    Instituto Chileno de Medicina Reproductiva (ICMER), José Victorino Lastarria 29, apt. 101, Santiago, Santiago, Chile, 8320165
    Search for articles by this author
  • J.L. Schwartz
    CONRAD/Eastern Virginia Medical School, 1911 Fort Myer Drive (Suite 900), Arlington, VA 22209
    Search for articles by this author
  • A. Fuentes
    Instituto de Investigaciones Materno Infantil (IDIMI), Faculty of Medicine Universidad de Chile, Santa Rosa 1234, Santiago, Santiago, Chile, 8360160
    Search for articles by this author
  • H.B. Croxatto
    Faculty of Medicine, Universidad Andrés Bello, Echaurren 283, Santiago, Santiago, Chile 8370071El 17-04-2014, a las 13:45
    Search for articles by this author



      Cyclooxygenase-2 (COX-2) is expressed in all female reproductive organs. Therefore, inhibitors of COX-2 may affect reproductive function. We evaluated the effect of extended administration of meloxicam on ovulation and the menstrual cycle. Our hypothesis was that meloxicam administered from menstrual cycle day 5- 22 could interfere with follicular rupture, without disrupting the menstrual cycle, and could be a potential non-hormonal contraceptive method.


      The study was conducted in 56 healthy sterilized women. Before the onset of treatment and after the end of treatment, participants were observed during a control cycle to ensure that they had progesterone (P4) serum levels (>12 nmol/l) consistent with ovulation. Participants were treated for 18 days, during three consecutive cycles. They were randomized to 15 or 30 mg/day. The menstrual cycle was monitored with serial ultrasound and hormone assays in blood.


      Fifty-six volunteers completed the study. In 55% of cycles treated with 15 mg/day and in 78% of cycles treated with 30mg/day (p<0.001) we observed dysfunctional ovulation defined as follicular rupture not preceded 24–48 h earlier by an LH peak or preceded by a blunted LH peak (<21 IU/l) or not followed by an elevated serum P4 level >12 nmol/l. Ovulation was observed in 44.6% and in 21.7% of women in the lower dose group and the higher dose group, respectively. There were no differences between the two doses in other parameters measured. There were no serious adverse events and adverse events were not different between doses or between control and treated cycles.


      Although administration of meloxicam on menstrual cycle days 5- 22 resulted in a dose-dependent inhibition of ovulation, more than 20% of subjects had normal ovulation with the highest dose.


      Previous studies have shown that oral meloxicam can delay follicle rupture. This study investigated daily oral meloxicam as a non-hormonal contraceptive. Since ovulation occurs in over 20% of cycles even with a high dose of 30 mg daily, it is not likely that the approach would be a highly effective contraceptive strategy.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Croxatto H.B.
        Female Reproductive Physiology/Function.
        in: Heggenhougen K. Quah S. Encyclopedia of Public Health. vol. 2. Academic Press, San Diego2008: 603-613
        • Armstrong D.T.
        Prostaglandins and follicular functions.
        J Reprod Fertil. 1981; 62: 283-291
        • Bata M.S.
        • Al-Ramahi M.
        • Salhab A.S.
        • Gharaibeh M.N.
        • Schwartz J.
        Delay of ovulation by meloxicam in healthy cycling volunteers: A placebo-controlled, double-blind, crossover study.
        J Clin Pharmacol. 2006; 46: 925-932
        • Jesam C.
        • Salvatierra A.M.
        • Schwartz J.L.
        • Croxatto H.B.
        Suppression of follicular rupture with meloxicam, a cyclooxygenase-2 inhibitor: potential for emergency contraception.
        Hum Reprod. 2010; 25: 368-373
        • Athanasiou S.
        • Bourne T.H.
        • Khalid A.
        • Okokon E.V.
        • Crayford T.J.
        • Hagström H.G.
        • et al.
        Effects of indomethacin on follicular structure, vascularity, and function over the periovulatory period in women.
        Fertil Steril. 1996; 65: 556-560
        • Pall M.
        • Fridén B.E.
        • Brännström M.
        Induction of delayed follicular rupture in the human by the selective COX-2 inhibitor rofecoxib: a randomized double-blind study.
        Hum Reprod. 2001; 16: 1323-1328
        • Dinchuk J.E.
        • Car B.D.
        • Focht R.J.
        • Johnston J.J.
        • Jaffee B.D.
        • Covington M.B.
        • et al.
        Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II.
        Nature. 1995; 378: 406-409
        • Ochsner S.A.
        • Russell D.L.
        • Day A.J.
        • Breyer R.M.
        • Richards J.S.
        Decreased expression of tumor necrosis factor-alpha-stimulated gene 6 in cumulus cells of the cyclooxygenase-2 and EP2 null mice.
        Endocrinology. 2003; 144: 1008-1019
        • Edelman A.
        • Jensen J.
        • Doom C.
        • Hennebold J.
        Impact of the prostaglandin synthase-2 inhibitor celecoxib on ovulation and luteal events in women.
        Contraception. 2013; 87: 352-357
        • Noé G.
        • Croxatto H.B.
        • Salvatierra A.M.
        • Reyes V.
        • Villarroel C.
        • Muñoz C.
        • et al.
        Contraceptive efficacy of emergency contraception with levonorgestrel given before or after ovulation.
        Contraception. 2011; 84: 484-492
        • Massai M.R.
        • Forcelledo M.L.
        • Brache V.
        • Tejada A.S.
        • Salvatierra A.M.
        • Reyes M.V.
        • et al.
        Does meloxicam increase the incidence of anovulation induced by single administration of levonorgestrel in emergency contraception? A pilot study.
        Hum Reprod. 2007; 22: 434-439
        • Hester K.E.
        • Harper M.J.
        • Duffy D.M.
        Oral administration of the cyclooxygenase-2 (COX-2) inhibitor meloxicam blocks ovulation in non-human primates when administered to simulate emergency contraception.
        Hum Reprod. 2010; 25: 360-367